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Abstract: Background/Aims: Chronic renal failure (CRF) patients develop anaemia, thus promoting cardiovascular 
complications, which seems to be favoured by the low kidney erythropoietin (EPO) production. The renal insufficiency 
degree might determine the moment to start recombinant human EPO (rhEPO) therapy. It has been attributed important 
non-hematopoietic effects to rhEPO, which might underlie cardio and renoprotection. This work aimed to evaluate the 
effect of rhEPO in a rat model of moderate CRF, focusing on inflammation, oxidative stress and function/renoprotection. 
Methods: Four groups (n=7) of male Wistar rats were evaluated during a 15 week follow-up period: control (without 
treatment); rhEPO (50 IU/Kg/wk Recormon
®
); CRF and CRF+rhEPO. Blood samples were collected at the beginning and 
3, 9 and 12 weeks after  nephrectomy, in order to evaluate: renal function, haematological parameters, iron metabolism 
and serum proliferative (TGF-1), inflammatory (TNF-, CRP, IL-2 and IL-1) and redox status (MDA, TAS and 3-NT) 
markers. Kidney gene expression of Il2, Vegf, Nos2 and Nos3 were assessed by real-time PCR. Blood pressure, heart rate 
and tissues trophy indexes were also estimated. 
Results: Our data are consistent with a sustained moderate degree of CRF with development of moderate and corrected 
anaemia and hypertension. The remnant kidney showed a proliferative profile, with increased mass (hypertrophism), 
upregulated tissue Vegf gene expression, accompanied by increased levels of serum TGF-1. Serum 3-NT was 
augmented, suggesting oxidative stress, which was accompanied by a trend to higher kidney Nos gene expression of both 
isoforms. rhEPO treatment was able to partially attenuate renal function markers, totally correct anaemia, also 
demonstrating a proliferative and antioxidant action, suggesting renoprotection. 
Conclusion: This study suggests that rhEPO therapy might be recommended in moderate CRF stages in order to 
efficiently correct not only the anaemia but also the underlying deleterious mechanisms, due to a proliferative and 
antioxidant action on the remnant kidney. 
Keywords: Moderate chronic renal failure, erythropoietin treatment, renoprotection, proliferation, inflammation, oxidative 
stress. 
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INTRODUCTION 
 Anaemia is a frequent complication associated with renal 
failure, and is mainly due to insufficient erythropoietin renal 
production. Accumulation of uremic toxins, excessive toxic 
storage of aluminium in the bone marrow [1], blood loss, and 
premature erythrocyte destruction have been also frequently 
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associated with anaemia of renal failure patients [2, 3]. This 
anaemia develops gradually, with the progressive decline of 
renal function [4-6] and EPO synthesis [4, 6]. Anaemia can 
lead to adverse clinical effects, namely, reduction in tissue 
oxygenation, increase in cardiac output, left ventricular 
hypertrophy, congestive heart disease, fatigue, reduction in 
exercise capacity, and immunodeficiency [7, 8]. 
 Until 18 years ago, the treatment of anaemia of renal 
failure was blood transfusion; since there, the management 
of this anaemia has been improved by the introduction of 
recombinant human erythropoietin (rhEPO) therapy. This 
therapy allowed a significant reduction in the associated 
adverse effects of anaemia and improved patient’s quality of 
life. 
 Currently, the main indication for rhEPO is the treatment 
of anaemia. However, an increasingly growing body of 
evidence indicates that therapeutic benefits of rhEPO could 
be far beyond correction of anaemia, namely in 
cardiovascular and nervous systems [9-11]. In fact, 
considering the wide distribution of erythropoietin receptor 
(EPOR) expression in body cells and tissues [12], it would 
be surprising if no effect were observed outside the erythroid 
cells. EPOR are also present in kidney tissue, especially on 
tubular cells [13]. It has been described that EPO activates 
different intracellular pathways in kidney tissue such as the 
PI3K/Akt pathway, a signalling pathway pivotal for cell 
survival, suggesting that administration of rhEPO could have 
also a protective effect in acute renal failure, such as 
ischemic injury, and in moderate stages of renal failure, 
contributing to organ protection/regeneration [14-16]. 
 The non-hematopoietic effects currently attributed to 
rhEPO therapy, known as a pleiotrophic action, might 
include and be important for a better cardio and 
renoprotection. This potential erythropoietin protective 
mechanism might be associated with a regenerative/ 
proliferative cell effect, and/or with anti-inflammatory and 
antioxidant properties. The aim of this work was to evaluate 
these potential rhEPO effects by studying inflammatory and 
redox status markers, as well as markers of renal 
function/renoprotection, by using a rat model of moderate 
renal failure induced by partial (3/4) nephrectomy, along a 
15 week protocol study. 
MATERIAL AND METHODS 
Animals and Experimental Protocol 
 Male Wistar rats (Charles River Lab. Inc., Barcelona, 
Spain), 250-300g, were maintained in an air conditioned 
room, subjected to 12-h dark/light cycles and given standard 
laboratory rat diet (IPM-R20, Letica, Barcelona, Spain) and 
free access to tap water. Animal experiments were conducted 
according to the European Communities Council Directives 
on Animal Care. 
 The rats were divided into 4 groups (7 rats each): a 
control, without drugs and surgery; a rhEPO (beta) group, 
treated with 50 IU/Kg/week Recormon
®
 (Roche 
Pharmaceuticals); a group with surgical CRF induced by a 
two-stage (3/4) nephrectomy: firstly, about half of the left 
kidney was removed by left flank incision and, one week 
later, the right kidney was removed through a right lateral 
flank incision; and at last a CRF+rhEPO group, which was 
treated with rhEPO after the 3
rd
 week of surgery All the 
animals have completed the 15-week protocol. Body weight 
(BW) was monitored during the study and blood pressure 
(BP) and heart rate (HR) measures using a tail-cuff 
sphygmomanometer LE 5001 (Letica, Barcelona, Spain). 
Sample Collection and Preparation 
 Blood: At the beginning of the experiments and at 3, 9 
and 12 weeks after the surgical partial nephrectomy the rats 
were subjected to intraperitoneal anesthesia with a 2 mg/kg 
BW of a 2:1 (v:v) 50 mg/mL ketamine (Ketalar
®
, Parke-
Davis, Lab. Pfeizer Lda, Seixal, Portugal) solution in 2.5% 
chlorpromazine (Largactil
®
, Rhône-Poulenc Rorer, Lab. 
Vitória, Amadora, Portugal). Blood samples were 
immediately collected by venipuncture from the jugular vein 
into syringes without anticoagulant (for serum sample 
collection) or with EDTA for haematological studies. 
 Tissues: The rats were sacrificed by cervical dislocation 
and the heart and kidneys were immediately removed, placed 
in ice-cold Krebs’ buffer and carefully cleaned of adherent 
fat and connective tissue. The BW, the whole heart weight 
(HW), the left ventricle weight (LVW) and the kidney 
weight (KW) were measured in order to be used as trophy 
indexes. 
Biochemical and Haematological Assays 
 Renal Function: Serum creatinine, ureia and uric acid 
concentrations were used as renal function indexes through 
automatic validated methods and equipments (Hitachi 717 
analyser). 
 Haematological Data: Red blood cell (RBC) count, 
haematocrit, haemoglobin (Hb) concentration, haemato-
logical indices [mean cell volume (MCV), mean cell Hb 
(MCH) and mean cell Hb concentration (MCHC)], red cell 
distribution width (RDW), reticulocyte count, immature 
reticulocyte fraction (IRF), platelets and white blood cell 
(WBC) counts were assessed in whole blood EDTA by using 
an automatic Coulter Counter
®
 (Beckman Coulter Inc., USA, 
CA). 
 Iron Metabolism: Serum iron concentration was 
determined using a colorimetric method (Iron, Randox 
Laboratories Ltd., North Ireland, UK), whereas serum 
ferritin and transferrin were measured by immunoturbi-
dimetry (Laboratories Ltd., North Ireland, UK). 
Inflammatory Markers and Redox Status 
 Serum levels of interleukin 2 (IL-2), IL-1, transforming 
growth factor 1 (TGF-1) and tumour necrosis factor  
(TNF-) were measured by ultrasensitive Quantikine® 
ELISA kits (R&D Systems, Minneapolis, USA). Serum C-
reactive protein (CRP) was determined by using an ELISA 
kit from Helica Biosystems, Inc. (Fullerton, CA, USA). All 
assays were performed in duplicate. 
 The thiobarbituric acid reactive-species (TBARs) assay 
was used to assess serum products of lipid peroxidation, 
namely malondialdehyde (MDA) [17]. Ferric reducing 
antioxidant potential (FRAP) assay was used to estimate 
serum total antioxidant status (TAS) [18]. Serum 3-
nitrotyrosine (3-NT), which is an index of peroxynitrite 
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formation, was measured by immunoassay (HyCult 
biotechnology b.v., Uden, Netherlands). 
Gene Expression Analysis 
 Total RNA Isolation: Kidneys were isolated in autopsy 
and stored in RNA later
TM
 solution (Ambion, Austin, USA). 
Samples were removed from preservation solution and 1200 
μl of RLT Lysis Buffer were added to proceed with 
disruption and homogenization for 2 minutes at 30Hz using 
TissueLyser (Qiagen, Hilden, Germany). Thirty milligrams 
of tissue lysate were processed according to the protocol 
from RNeasy
®
 Mini Kit (Qiagen, Hilden, Germany) for 
Isolation of Total RNA extraction from animal tissues and 
total RNA was eluted in 50 l of RNase-free water (without 
optional treatment with DNAse). In order to quantify the 
amount of total RNA extracted and verify RNA integrity 
(RIN, RNA Integrity Number), samples were analyzed using 
6000 Nano Chip
®
 kit, in Agilent 2100 bioanalyzer (Agilent 
Technologies, Walbronn, Germany) and 2100 expert 
software, following manufacturer instructions. The yield 
from isolation was from 0.5 to 3 g; RIN values were 6.0-9.0 
and purity (A260/A280) was 1.8-2.0. 
 Reverse Transcription: RNA was reverse transcribed 
with SuperScript
TM
 III First-Strand Synthesis System for RT-
PCR (Invitrogen, California, USA). One microgram of total 
RNA was mixed with a 2X First-Strand Reaction Mix 
(Oligo(dT) plus Random hexamers) and a SuperScript™ III 
Enzyme Mix, according to manufacturer instructions. 
Reactions were carried out in a thermocycler Gene Amp 
PCR System 9600 (Perkin Elmer, Norwalk, USA), 10 min at 
25 ºC, 50 min at 50 ºC and 5 min at 85 ºC. Reaction products 
were then digested with 1 l RNase H for 20 min at 37 ºC 
and, finally, cDNA eluted to a final volume of 100 μl and 
stored at -20ºC. 
 Relative Quantification of Gene Expression: Relative 
quantification of gene expression by real-time PCR was 
performed using 7900 HT Sequence Detection System 
(Applied Biosystems, Foster City, USA). A normalization 
step preceded the gene expression quantification, using 
geNorm Housekeeping Gene Selection kit for Rattus 
norvegicus (Primer Design, Southampton, United Kingdom) 
and geNorm software (Ghent University Hospital, Center for 
Medical Genetics, Ghent, Belgium) to select optimal 
housekeeping genes to this study [19]. 
 
 Real-time PCR reactions used optimized specific primers 
(Proligo, Boulder, USA) for genes of interest Nos2, Nos3, 
Vegf and Il2 and endogenous controls Actb, Gapdh, Top1 
(Table 1) together with QuantiTect SYBR Green PCR Kit 
Gene expression. Real-time PCR reactions were carried out 
with: 100ng cDNA sample, primers (50-200 nM) and 1X 
QuantiTect SYBR Green PCR Master Mix. Non template 
control reactions were performed for each gene, in order to 
assure no unspecific amplification. Reactions were 
performed with the following thermal profile: 10 minutes at 
95ºC plus 40 cycles of 15 seconds at 95ºC and 1 minute at 
60ºC. Real-time PCR results were analyzed with SDS 2.1 
software (Applied Biosystems, Foster City, USA) and 
quantification used the 2
-Ct
 method [20]. Mann-Whitney U 
test was computed in SPSS 15.0 (SPSS Inc., Chicago, USA) 
to test differences between groups (p<0.05). 
Data Analysis 
 For statistical analysis, we used the Statview 4.53 
software from Abacus Concepts Inc. (Berkeley, CA, USA). 
Results are presented as mean ± s.e.m. Comparisons between 
groups and different times were performed using one-way 
ANOVA and Fisher’s test. Significance was accepted at p 
less than 0.05. 
RESULTS 
 We analysed the results in two ways, one to evaluate the 
changes imposed by rhEPO treatment and by nephrectomy-
induced renal failure (rhEPO and CRF groups vs control); 
and the other to evaluate the changes induced by rhEPO 
treatment in CRF rats (rhEPO+CRF vs control). 
Biochemical and Haematological Data 
 In Table 2 we present the renal function markers, 
haematological data and iron metabolism, for the different 
groups, before starting experiments and at the end of the 
experimental period (15 weeks: 12 weeks after partial 
nephrectomy). There was a statistically significant increase 
in serum creatinine and urea concentrations at the three 
weeks after surgery (data not shown), and this increase in 
renal function markers remained high along the following 12 
weeks of the experimental procedure. The rhEPO treatment 
in the CRF animals produced no significant effects in those 
parameters (Table 2). 
 
Table 1. Genes of Interest and Endogenous Controls Used in the Present RT-qPCR Study (Gene Symbol, Name, GenBank 
Number and Primers Sequences) 
 
Gene 
Symbol 
Gene Name 
GenBank 
Number 
Forward Primer Sequence 
(5’-3’) 
Reverse Primer 
Sequence (5’-3’) 
Amplicon 
Length (bp) 
Il2 Interleukin 2 NM_053836 tggggagtttcagattcttgtaat ctgcaaaggaaacacagcag 96 
Nos2 Nitric oxide synthase 2, inducible NM_012611 ttcttggcgtggatgctg gctacacttccaacgcaaca 113 
Nos3 Nitric oxide synthase 3, endothelial cell  NM_021838 cgggtgtctagatccatgc tgaccctcaccgatacaaca 60 
Vegf Vascular endothelial growth factor NM_031836 tttctccgctctgaacaagg aaaaacgaaagcgcaagaaa 63 
Actb Actin beta NM_031144  
Gapdh Glyceraldehyde-3-phosphate dehydrogenase NM_017008 
Primers from geNorm Housekeeping Gene Selection kit 
 
Top1 Topoisomerase I NM_022615   
28    The Open Drug Discovery Journal, 2010, Volume 2 Garrido et al. 
 Concerning to haematological data, 3 weeks after 
nephrectomy, the CRF animals showed a statistically 
significant decrease for RBC count, HTC and Hb, alongside 
with a significantly increase in platelet count and RDW (data 
not shown). These parameters normalized in the laboratorial 
evaluation performed 9 weeks after surgical intervention and 
remained stables until the end of the follow-up period. No 
statistically significant differences were found for total WBC 
counts. The rhEPO treatment in the CRF animals 
(CRF+rhEPO group) showed a trend to increased 
haematological values (RBC, HTC and Hb) (Table 2). 
 The evaluation of iron metabolism in CRF rats, showed 
no alterations in iron serum levels, a progressively increase 
in ferritin content, which reached statistical significance at 
15 weeks (12 weeks after surgery). On the contrary, at the 
end of the follow-up period, transferrin serum levels were 
significantly lower in CRF animals than those of the control 
rats (Table 2). Furthermore, the treatment of CRF rats with 
rhEPO produced no effects in iron serum levels, but 
increased significantly ferritin, when compared with the CRF 
group. In addition, the transferrin levels were higher in 
CRF+rhEPO rats than in CRF animals, but without statistical 
significance (Table 2). 
Blood Pressure, Heart Rate and Tissue Trophy Indexes 
 A statistically significant increase in SBP, DBP, MBP 
and HR were also found in CRF rats, together with an 
increase in heart and left ventricle weights, and without 
differences in the tissue trophy indexes (Table 3). The rats 
only treated with rhEPO have significantly increased the 
SBP, DBP, MBP and HR. The rhEPO treatment in the CRF 
rats (CRF+rhEPO group) showed a trend to attenuate the 
blood pressure values and significantly (P<0.05) corrected 
HR values. This group (CRF+rhEPO) still showed a trend to 
increased values of kidney weight and KW/BW tissue trophy 
index when compared with CRF group (Table 3). 
Inflammatory Markers and Redox Status 
 Concerning inflammatory markers, no significant 
differences for CRP, IL-1, IL-2 and TNF- serum levels 
were observed, but an increased concentration of TGF-1 
was found in the CRF rats vs the control group. The rhEPO 
treatment of CRF rats produced no significant changes for 
CRP, IL-1, IL-2 and TNF- serum concentration 
(CRF+rhEPO group), but imposed a further increase 
(P<0.01) in the TGF-1 value, found in the CRF animals 
(Table 3). 
Table 2. Effects of rhEPO Treatment in Renal Function, Hematological Data and Iron Metabolism in a Rat Model of Moderate 
CRF 
 
Initial Time (0 Weeks) Final Time (15 Weeks)  
Before  N Without  N  With  N Parameters 
All the Rats Controls rhEPO CRF CRF+rhEPO 
Renal Function 
Creatinine (mol/L) 36.24 ± 1.78 39.78 ± 1.77 38.90 ± 2.64  80.44 ± 5.30 aa 64.53 ± 2.65 
Urea (mmol/L) 14.63 ± 0.24 13.93 ± 0.56 13.78 ± 0.61  24.21 ± 1.01 a 22.49 ± 0.99 
Uric acid (mol/L) 35.69 ± 3.57 36.88 ± 9.52 49.37 ± 8.33 28.55 ± 5.35 36.88 ± 5.95 
Haematological Data 
Hb (g/L) 138.21 ± 1.42 139.44 ± 3.61 128.72 ± 5.29 134.39 ± 2.01 148.81 ± 17.20 
Haematocrit (L/L) 0.395 ± 0.005 0.409 ± 0.007 0.361 ± 0.017 0.395 ± 0.006 0.439 ± 0.056 
RBC (x1012/L) 7.32 ± 0.12 7.44 ± 0.10 6.84 ± 0.38 6.91 ± 0.14 7.83 ± 0.94 
MCV (fL) 53.95 ± 0.62 55.04 ± 1.32 53.08 ± 0.73 57.27 ± 0.66 55.75 ± 0.78 
MCH (pg) 18.85 ± 0.25 18.74 ± 0.61 18.90 ± 0.30 19.48 ± 0.28 19.06 ± 0.21 
MCHC (g/dL) 34.93 ± 0.19 34.04 ± 0.37 35.60 ± 0.21aaa 34.00 ± 0.30 34.21 ± 0.47 
RDW (%) 13.3 ± 0.4 14.9 ± 0.4 15.3 ± 0.7 13.5 ± 0.2 15.2 ± 1.2 
Reticulocytes (x109/L) 389.01 ± 29.10 383.98 ± 28.97 286.04 ± 22.01 326.09 ± 27.02 228.08 ± 17.98 
IRF (%) 0.38 ± 0.02 0.38 ± 0.01 0.41 ± 0.02 0.56 ± 0.09 0.42 ± 0.07 
Platelets (x109/L) 980.50 ± 22.79 980.40 ± 33.07 1007.00 ± 56.85 943.85 ± 78.49 888.66 ± 90.17 
WBC (x109/L) 6.87 ± 1.19 5.14 ± 0.22 2.27 ± 1.07 a 5.53 ± 0.85 5.05 ± 0.91 
Iron Metabolism 
Iron (μmol/L) 27.42 ± 2.31 27.60 ± 4.82 29.09 ± 1.35 22.29 ± 2.13 21.05 ± 4.10 
Ferritin (pmol/L) 28.38 ± 3.03 29.03 ± 8.27 408.19 ± 29.62 aaa 55.41 ± 11.95 a 267.62 ± 7.86 bbb 
Transferrin (g/L) 1.30 ± 0.04  1.20 ± 0.08 1.22 ± 0.03 0.81 ± 0.11 aaa 0.98 ± 0.12 
N: nephrectomy. Results are mean ± s.e.m. of 7 rats for each group: a - p< 0.05, aa - p< 0.01 and aaa - p< 0.001 vs the control group; b - p< 0.05, bb - p< 0.01 and bbb- p< 0.001 vs 
the CRF group. 
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 No statistically significant changes were found between 
CRF and control group for MDA and TAS, but a 
significantly (P<0.05) higher serum concentration of 3-NT 
was found. The rhEPO treatment in CRF rats (CRF+rhEPO 
group) showed a trend to increased serum concentration of 
MDA and TAS, although no significant evidences were 
observed between the groups. However, a statistically 
significant reduction of serum 3-NT levels was found 
between the group of CRF with rhEPO and those without 
rhEPO therapy (Table 3). 
Real Time-PCR Gene Expression 
 The kidney gene expression of the inflammatory 
biomarker Il2 was upregulated in CRF (P<0.05, without 
significant changes in the group under rhEPO treatment after 
nephrectomy. rhEPO treatment, alone, was able to reduce Il2 
gene expression below the control levels (Fig. 1). Vegf gene 
was upregulated (P<0.05) in the kidney tissue from CRF and 
CRF+rhEPO groups, in respect to the downregulation 
observed for the EPO group. Kidney Nos2 and Nos3 gene 
expression were not significantly altered in the rhEPO group 
vs the control. However, there was a trend to higher values in 
the CRF group, without a consistent reduction when rhEPO 
was given to CRF rats (Fig. 1). 
DISCUSSION 
 In chronic kidney disease (CKD) patients, anemia has 
been identified as an independent risk factor for progression 
of the disease, as it conditions tissue hypoxia, and, therefore, 
may contribute or perpetuate preexisting renal tissue injury 
[21]. There is some evidence suggesting that rhEPO therapy 
is able to retard progression of renal failure. However, there 
are some controversial results about this subject [22], which 
can be related to distinct molecular pathways and/or to EPO 
Table 3. Effects of rhEPO Treatment on Blood Pressure, Heart Rate, Tissue Trophy Indexes and Inflammatory and Redox Status 
Markers in a Rat Model of Moderate CRF 
 
Final Time - 15 Weeks 
No Surgery With  N Parameters 
Control rhEPO CRF CRF+rhEPO 
Blood Pressures and HR  
SBP (mmHg) 114.88 ± 3.08  135.96 ± 3.07aaa 143.07 ± 4.61aaa 139.71 ± 3.33 
DBP (mmHg)  99.11 ± 1.76 109.55 ± 4.51a 123.31 ± 12.38aa 113.21 ± 0.96 
MBP (mmHg) 104.33 ± 1.89  117.78 ± 3.80aa 129.64 ± 9.79aaa 121.69 ± 0.78 
HR (beats/min.) 339.12 ± 6.28  380.00 ± 2.56aaa 391.89 ± 12.00aaa 357.40 ± 2.88b 
Body and Tissue Weights 
BW (Kg)  0.47 ± 0.02 0.49 ± 0.02 0.46 ± 0.01 0.48 ± 0.03 
HW (g)  1.21 ± 0.03 1.37 ± 0.11 1.46 ± 0.06a 1.48 ± 0,08 
LVW (g)   0.57 ± 0.03 0.48 ± 0.06 0.72 ± 0.04a 0.71 ± 0.04 
KW (g)  1.24 ± 0.04 1.28 ± 0.06 1.94 ± 0.20 2.21 ± 0.47 
Tissue Trophy Indexes 
HW/BW (g/kg)  2.65 ± 0.07 2.80 ± 0.17 2.98 ± 0.10 3.13 ± 0.31 
LVW/HW (g/kg)  0.47 ± 0.02  0.36 ± 0.05a 0.50 ± 0.02 0.48 ± 0.02 
LVW/BW (g/kg)  1.05 ± 0.11 0.98 ± 0.10 1.17 ± 0.14 1. 36 ± 0.20 
KW/BW (g/kg)  2.62 ± 0.05 2.63 ± 0.08 3.96 ± 0.39 5.12 ± 1.49 
Inflammatory Profile 
CRP (μg/ml) 24.78 ± 1.25 24.47 ± 0.90  25.83 ± 0.66 26.93 ± 0.98 
IL-1 (pg/ml) 26.52 ± 0.94 26.19 ± 0.99  23.76 ± 0.99 27.50 ± 0.95 
IL-2 (pg/ml) 36.28 ± 8.70 47.35 ± 3.50  49.34 ± 3.43 47.19 ± 3.50 
TGF-1 (pg/ml) 358.41 ± 34.52 395.91 ± 21.56  544.42 ± 50.43 a 734.47 ± 30.99b 
TNF- (pg/ml) 16.34 ± 1.81 17.56 ± 2.12  15.75 ± 1.96 19.85 ± 2.44 
Redox Status 
MDA (μmol/l)  0.27 ± 0.05 0.40 ± 0.05  0.34 ± 0.06 0.46 ± 0.10 
TAS (μmol/l) 394.72 ± 51.42 475.89 ± 122.14  408.03 ± 23.62 431.19 ± 41.82 
MDA/TAS   0.56 ± 0.05 0.99 ± 0.17  0.73 ± 0.21 0.94 ± 0.18 
3-NT (nmol/l) 15.66 ± 1.40 33.37 ± 5.46  50.45 ± 3.22 aaa 17.08 ± 4.34bb 
N: nephrectomy. Results are mean ± s.e.m. of 7 rats for each group: a - p< 0.05, aa - p< 0.01 and aaa - p< 0.001 vs the control group; b - p< 0.05, bb - p< 0.01 and bbb - p< 0.001 vs 
the CRF group. 
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tissue receptor affinities that mediate the effect of EPO on 
erythropoiesis and on tissue protection. 
 The studies of the effect of rhEPO in non-erythroid 
tissues are very difficult to perform in human subjects, 
justifying the development of animal models. In this work, 
an evaluation of the effect of rhEPO on blood inflammatory 
and oxidative stress markers, and on a potential 
renoprotection, was performed, by using a rat model of 
moderate renal failure. 
 Our model of surgical partial (3/4) nephrectromy 
produces a moderate, but sustained stage of chronic renal 
failure. Indeed, we observed a significant increase in serum 
urea and creatinine concentrations at 3 weeks after the 
surgery, in CRF and CRF+rhEPO groups that remained 
almost constant during the following period. However, in 
CRF+rhEPO rats, a decrease in creatinine serum levels was 
observed after 12 weeks of rhEPO treatment, suggesting a 
slight recovery of renal function associated to this treatment. 
 Anaemia is a common complication associated with 
CKD. It has also a negative impact on cardiovascular 
system, cognitive function, exercise capacity and quality of 
life, resulting in a significant morbidity and mortality in 
these patients [7, 8]. This anaemia is mainly determined by 
the rate of renal insufficiency and, therefore, by the reduction 
 
Fig. (1). Relative gene expression quantification for Interleukin-2 (A), Vegf (B), Nos2 (C) and Nos3 (D) in rhEPO, CRF and CRF+rhEPO 
groups comparatively to control group (zero line). Values are expressed in logarithmic scale. a - p< 0.05 vs the control group; b - p< 0.05 vs 
the rhEPO group. 
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in the renal secretion of erythropoietin. In our CRF rats, we 
found a decrease in RBC count, Hb concentration and HTC, 
3 weeks after nephrectomy, consistent with the development 
of anaemia secondary to renal mass reduction; moreover, the 
number of reticulocytes, as well as the percentage of 
immature reticulocytes did not increase, further supporting a 
failure of the erytropoietic response mechanisms, due to 
insufficient erythropoietin production associated to the 
reduction in renal tissue. However, the anaemia is 
notoriously transitory, as RBC count, HTC and Hb returned 
to the normal values at 9 weeks of study (data not shown) 
and sustained their values at 15 weeks of study, in both CRF 
and CRF+rhEPO rat groups. These results suggests that the 
remaining kidney is able to maintain EPO production in a 
sufficient amount to support erythropoiesis, that seems to be 
slightly accelerated in CRF rats as compared to CRF rats 
with rhEPO treatment, as suggested by the trend towards 
higher values of immature reticulocytes observed in CRF 
rats. Moreover, we found a trend for an increased kidney 
weight (hypertrophy), increased serum levels of TGF-1 and 
kidney expression of Vegf markers, further suggesting an 
increase in renal tissue proliferation/hypertrophy, consistent 
with a compensated renal insufficiency. Serum levels of 
TGF-1 are significantly higher in CRF rats treated with 
rhEPO, suggesting that rhEPO may contribute to increase 
remnant kidney hypertrophy and/or have a systemic induced 
proliferative activity. This observation suggests a probable 
mechanism contributing for relative renal recovery function 
associated to rhEPO treatment. 
 Besides the anaemia secondary to renal failure, CKD 
patients usually develop cardiac failure that further worsens 
renal disease. This triad of dysfunctions, already known as 
cardio-renal anaemia syndrome, is responsible for the serious 
complications observed in these patients [23-25]. 
Hypertension is a well established cause of CVD, a common 
complication in CKD, and, therefore, an important risk 
factor for progression of the cardiovascular complications 
and mortality of CKD patients [26]. Additionally, treatment 
with rhEPO has also been associated with hypertension [27-
29]. Our results confirmed these conditions, with increased 
blood pressure (systolic and diastolic), together with 
tachycardia and heart and left ventricle hypertrophy, in both 
groups of CRF rats (with and without rhEPO treatment). 
However, the heart rate increase in the CRF rats was 
prevented in the group under rhEPO treatment, which might 
be due to a reduction of sympathetic overactivity, a common 
feature observed in CKD patients [30] that might result from 
the preventive effect of rhEPO on the development of 
anaemia and heart insufficiency. It seems that rhEPO 
promotes heart hypertrophy, thus compensating the putative 
insufficiency that anaemia could originate. 
 In CKD patients under haemodialysis, inflammation and 
oxidative stress are consistent findings and could play a 
crucial role in the pathogenesis of atherosclerosis, 
malnutrition and anaemia in these patients [31]. 
Additionally, an enhancement in these conditions has been 
associated with resistance to rhEPO treatment [32-34]. Our 
CRF rats, after 12 weeks of partial nephrectomy, showed 
normal blood values for the studied inflammatory markers, 
except TGF-1 that, as previously referred, may reflect an 
underlying proliferative recovering process of the renal 
tissue, which should be further confirmed by testing the gene 
expression or the levels produced by the kidney. However, at 
the kidney tissue level, CRF rats presented a higher gene 
expression of Il2, a pro-inflammatory cytokine, suggesting 
that a residual inflammation still persists. Moreover, a higher 
Vegf gene expression was also observed, further 
strengthening a proliferative recovering process of the renal 
tissue and the need to counterbalance hypoxia at kidney level 
by inducing angiogenesis. Our results also showed that the 
rhEPO treatment did not interfere with these changes neither 
at blood level nor at kidney levels. However, rhEPO 
treatment along a CRF condition seem to gain an active role 
as suggested by the even higher blood values (as compared 
to CRF rats) of TGF-1; at kidney tissue it seems to play 
also a protective role, as suggested by the trend to lower 
values (though without statistical significance) for the gene 
expression of Il2 and the higher for Vegf. 
 The continuous administration of rhEPO in rats did not 
induce erythrocytosis after 15 weeks of treatment, though 
some changes were observed in iron metabolism, namely a 
significant increase in iron storages, as showed by ferritin 
values. We may hypothesize that a negative feedback 
mechanism may develop, reducing the mobilization of iron 
from the storage pool, in order to maintain normal values of 
circulating erythrocytes, reducing, therefore, the risk 
associated with a high blood viscosity [35]. We believe this 
can not be due to the development of anti-rhEPO antibodies, 
as this is usually associated to a severe anemia [35]. 
Actually, in CRF rats treated also with rhEPO, the same 
changes were observed after 15 weeks of treatment, though 
in a reduced way that is probably due to the reduced 
contribution of endogenous EPO. The group of rats with 
only CRF, when compared to control presented higher 
values of ferritin (though about five times lower than the 
values presented by CRF+rhEPO group), lower values 
transferrin and a trend to lower values of seric iron. These 
changes, usually described for inflammatory processes, may 
reflect the low grade inflammation observed in these 
patients. 
 In our CRF rats, the redox state seems to be unaltered 
(MDA/TAS ratio was unchanged), which might be due to a 
proper compensation, to remove ROS by antioxidants, 
eventually resulting from the moderate renal failure 
condition. However, there was an increase in serum 3-NT 
value, which is a marker of peroxynitrite generation, and, 
thus, might hypothetically reflect an increased superoxide 
formation and, thus, a reduced NO availability, since this 
dangerous oxidant is formed by the combination of both. 
Furthermore, the trend to increased gene expression of both 
Nos isoforms in the remnant kidney of CRF, might suggests 
an increment of NO, thus contributing to peroxynitrite 
formation when superoxide is abundant. On the other hand, 
the trend to increment in kidney gene expression of the 
inducible Nos isoforms might also be viewed as an 
additional confirmation of the existence of a kidney 
inflammatory response in this model of moderate renal 
failure. The putative importance of this response and the 
character of the results now obtained deserve further efforts 
in order to clarify both the inflammatory response and the 
involvement of NO in this profile. The treatment with rhEPO 
in the CRF rats has decreased serum 3-NT levels, suggesting 
an antioxidative effect of erythropoietin, despite no 
correction of Nos overexpression. 
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 In conclusion, our data are consistent with a model of 
moderate, but sustained, degree of chronic renal failure, with 
development of moderate and corrected anaemia and 
hypertension. This was accompanied by low grade 
inflammatory and pro-oxidative processes at blood level and, 
at kidney tissue level a proliferative/recovering stimuli, 
which might be viewed as a compensatory phenomenon. In 
this model, rhEPO treatment was able to partially improve 
renal function, to correct anaemia, and to have a proliferative 
and antioxidant action. Since the pathophysiological 
modifications underlying CRF seems to be dependent on the 
insufficiency degree, this study suggests that rhEPO therapy 
might be recommended in moderate CRF stages in order to 
efficiently correct not only the anaemia but also the 
underlying deleterious mechanisms, thus demonstrating a 
pleiotrophic renoprotective action. 
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